The American Cancer Society estimates that over 80,000 individuals will be diagnosed with bladder cancer this year.

A large U.S. health records study suggests that difficulty seeing blood in urine may put color-blind patients at higher risk.

An update from the phase 2 LEGEND trial shows that the investigational nonviral gene therapy detalimogene voraplasmid has achieved a 62% complete response rate at six months in patients with high-risk ...

Valar Labs, a leader in AI-powered diagnostics for oncology, today announced a strategic partnership with PathNet Lab, one of the nation’s foremost pathology laboratories. Through this collaboration, ...

A retrospective cohort study suggested that people with color blindness may have a higher risk of mortality from bladder ...

What Is Zusduri Used For? Zusduri is used to treat a certain type of recurrent, persistent bladder cancer known as LG-IR-NMIBC. About 75% of people with bladder cancer present with non-muscle invasive ...

WILMINGTON, Del.--(BUSINESS WIRE)--Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s IMFINZI ® (durvalumab), administered perioperatively in ...

The extent of the bladder cancer — how far it has spread — matters. Your care team needs to know if your cancer sits on or in the first lining of your bladder (non-muscle invasive), if it goes into ...

Alpenglow Biosciences, the leader in clinical-grade 3D digital pathology and AI-powered spatial analytics, and PathNet, one of the nation’s foremost pathology laboratories and largest ...

When you learn you have bladder cancer, it’s only natural to ask: "Can I survive this, for how long, and can I expect to be cured?" You may have searched online for survival rate information. These ...

IMFINZI was generally well tolerated, and no new safety signals were observed in the neoadjuvant and adjuvant settings. Further, adding IMFINZI to neoadjuvant chemotherapy was consistent with the ...